Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
Blood Advances
|
July 11, 2022
Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis
Nazila Shafagati, Min J Koh, Leora Boussi, et al.
Blood Neoplasia
|
June 24, 2025
Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia
Kuo-Kai Chin, Yannis Valtis, Andriy Derkach, et al.
American Journal of Hematology
|
August 23, 2021
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma
Peter A Forsberg, Adriana C Rossi, Angelique Boyer, et al.
Blood Advances
|
April 8, 2025
Patients with AML and an IDH2-R172 Mutation Exhibit a Unique Initial Response to Intensive Chemotherapy Induction
Meira Yisraeli Salman, Alexander R Terry, Andriy Derkach, et al.
American Journal of Hematology
|
February 12, 2019
Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma
Peter A Forsberg, Adriana C Rossi, Angelique Boyer, et al.
Cancer
|
August 7, 2025
Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs
Hannah Burton, Leora Boussi, David Nemirovsky, et al.
Blood
|
March 2, 2023
Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease
Anita G Koshy, Haesook T Kim, Jessica Liegel, et al.
Haematologica
|
January 29, 2026
Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities
Leora Boussi, Jan Philipp Bewersdorf, Yiwen Liu, et al.
Blood Neoplasia
|
March 20, 2026
Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics
Luis E Aguirre, Jan Philipp Bewersdorf, Yiwen Liu, et al.
JAMA Oncology
|
May 15, 2025
Barriers to Chimeric Antigen Receptor T-Cell Therapy
Yannis K Valtis, Kuo-Kai Chin, David Nemirovsky, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
Blood Advances
|
July 11, 2022
Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis
Nazila Shafagati, Min J Koh, Leora Boussi, et al.
Blood Neoplasia
|
June 24, 2025
Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia
Kuo-Kai Chin, Yannis Valtis, Andriy Derkach, et al.
American Journal of Hematology
|
August 23, 2021
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma
Peter A Forsberg, Adriana C Rossi, Angelique Boyer, et al.
Blood Advances
|
April 8, 2025
Patients with AML and an IDH2-R172 Mutation Exhibit a Unique Initial Response to Intensive Chemotherapy Induction
Meira Yisraeli Salman, Alexander R Terry, Andriy Derkach, et al.
American Journal of Hematology
|
February 12, 2019
Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma
Peter A Forsberg, Adriana C Rossi, Angelique Boyer, et al.
Cancer
|
August 7, 2025
Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs
Hannah Burton, Leora Boussi, David Nemirovsky, et al.
Blood
|
March 2, 2023
Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease
Anita G Koshy, Haesook T Kim, Jessica Liegel, et al.
Haematologica
|
January 29, 2026
Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities
Leora Boussi, Jan Philipp Bewersdorf, Yiwen Liu, et al.
Blood Neoplasia
|
March 20, 2026
Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics
Luis E Aguirre, Jan Philipp Bewersdorf, Yiwen Liu, et al.
JAMA Oncology
|
May 15, 2025
Barriers to Chimeric Antigen Receptor T-Cell Therapy
Yannis K Valtis, Kuo-Kai Chin, David Nemirovsky, et al.
Page
of 3